DARE news

Dare Bioscience cancelled its Single-Use Diagnostics pipeline and intends to pursue strategic alternatives for its portfolio, signaling a shift in its corporate focus.

Dare Bioscience amended its bylaws to establish a quorum allowing for virtual meetings, effective as of September 10, 2026. This move enables shareholders to participate remotely via proxy, enhancing corporate governance flexibility.

Dare Bioscience failed to meet the registration deadline for biomX Inc. as a part of its proposed special purpose acquisition company merger; the company has now filed the necessary materials with the SEC and the Bank of Greece to remedy the issue.

Dare Bioscience has entered a funding and collaboration agreement with Ravenna Pharma to evaluate a proprietary theranostic platform for the Cardiovascular Age at Risk (CVaR) tumor staging project. This partnership is significant as it introduces advanced imaging capabilities to Dare's stage 3 clini…

Dare Bioscience inc. has submitted the exhibit. Market impact cannot be assessed without the full document text.

Dare Bioscience submitted an exhibit filing with the SEC. The filing appears to contain material information requiring public disclosure.